Prime Medicine
PRME
79 hedge funds and large institutions have $676M invested in Prime Medicine in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 13 closing their positions.
177% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 13
32% more capital invested
Capital invested by funds: $512M → $676M (+$164M)
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
4.53% more ownership
Funds ownership: 42.92% → 47.45% (+4.5%)
4% more funds holding
Funds holding: 76 → 79 (+3)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$34.2M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$28.8M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$28.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20M |
| 5 |
BlackRock
New York
|
+$19.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$62.5M |
| 2 |
AI
Alphabet Inc
Mountain View,
California
|
-$19.9M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$9.33M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.03M |
| 5 |
CC
Casdin Capital
New York
|
-$5.13M |
PRME Hedge Fund Activity: Q2 2023 in Review
79 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q2 2023, worth a combined $676M — up 32% from $512M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PRME positions and 13 closed out — a net gain of 3 holders — while 36 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $34.2M. The largest seller was Fidelity Investments, cutting an estimated $62.5M.
- 79 institutional investors held Prime Medicine (PRME) as of Q2 2023, up from 76 in Q1 2023.
- Funds reported $676M of Prime Medicine stock for Q2 2023, up 32% quarter-over-quarter.
- 16 funds opened new Prime Medicine positions in Q2 2023 and 13 closed out, a net change of +3 holders.
- The largest Prime Medicine buyer in Q2 2023 was Vanguard Group, an estimated $34.2M added.
- The largest Prime Medicine seller in Q2 2023 was Fidelity Investments, an estimated $62.5M sold.
Based on aggregated 13F filings for Q2 2023.